Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ... Approval ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

It was a pleasure getting to know the true Indira Gandhi through the lens of Kangana Ranaut. She effortlessly fitted into the role with her facial expressions and nasal twang. Emergency highlights the ...

LONDON - UK patients are “coming to harm” with hospitals so overwhelmed people are dying in corridors awaiting treatment amid a “collapse in care standards”, a report said on Jan 16.

Tearful nurses told an RCN briefing in central London of being powerless as patients spend hours slowly dying on a trolley in a busy corridor and finding a dead patient under a pile of coats.

Esketamine, the ketamine-derived nasal spray sold under the brand name Spravato (esketamine), is indicated for patients with treatment-resistant depression. In October 2023, the FDA warned about ...